Cohbar [CWBR] vs Regeneron [REGN] Detailed Stock Comparison

Cohbar Inc

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Cohbar Inc wins in 3 metrics, Regeneron Pharmaceuticals, Inc. wins in 11 metrics, with 1 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Cohbar Inc Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) -0.10 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 0.13 2.45 Cohbar Inc
Debt-to-Equity Ratio 0.00 9.51 Tie
PEG Ratio -0.10 -4.80 Cohbar Inc
EV/EBITDA 0.85 16.72 Cohbar Inc
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 0.00% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -83.97% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -48.31% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-10.45M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return -62.94% 15.66% Regeneron Pharmaceuticals, Inc.
Price-to-Sales Ratio (TTM) N/A 5.50 N/A
Enterprise Value $-11.12M $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio N/A 4.95 N/A
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-4.37 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 1.38 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float N/A 2.55% N/A

Cohbar Inc vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

CWBR
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Cohbar Inc0.00%N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Cohbar Inc-62.94%-79.18%-79.18%-79.18%-79.18%-79.18%
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%

Performance & Financial Health Analysis: Cohbar Inc vs Regeneron Pharmaceuticals, Inc.

MetricCWBRREGN
Market Information
Market Cap iN/A$80.98B
Market Cap CategoryN/ALarge cap
10 Day Avg. Volume i60642,495
90 Day Avg. Volume i3,344617,765
Last Close$0.41$614.98
52 Week Range$0.20 - $1.01$503.25 - $821.11
% from 52W High-59.41%-25.10%
All-Time High$323.67 (Jun 11, 2018)$1,211.20 (Aug 26, 2024)
% from All-Time High-99.87%-49.23%
Growth Metrics
Quarterly Revenue GrowthN/A0.03%
Quarterly Earnings GrowthN/A-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i0.00%0.23%
Return on Equity (TTM) i-0.84%0.15%
Debt to Equity (MRQ) i0.009.51
Cash & Liquidity
Book Value per Share (MRQ)$3.27$304.65
Cash per Share (MRQ)$4.24$83.86
Operating Cash Flow (TTM) i$-7,940,233$4.98B
Levered Free Cash Flow (TTM) i$-3,498,595$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Cohbar Inc vs Regeneron Pharmaceuticals, Inc.

MetricCWBR (Mar 31, 2025)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-0.1018.00
Forward P/E i-0.1014.21
PEG Ratio i-0.10-4.80
Price to Sales (TTM) iN/A5.50
Price to Book (MRQ) i0.132.45
Market Capitalization
Market Capitalization i$1.19M$80.98B
Enterprise Value i$-11,119,515$70.98B
Enterprise Value Metrics
Enterprise to Revenue iN/A4.95
Enterprise to EBITDA i0.8516.72
Risk & Other Metrics
Beta i1.380.40
Book Value per Share (MRQ) i$3.27$304.65

Financial Statements Comparison: Cohbar Inc vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCWBR (2022)REGN (2025)
Revenue/Sales i014.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i-14.6%
Gross Profit iN/A12.24B
Gross Margin i-85.4%
Research & Development i5.94M5.85B
Operating Income (EBIT) i-12.39M3.70B
Operating Margin i-25.8%
EBITDA i-12.07M5.00B
EBITDA Margin i-34.8%
Pre-Tax Income i-12.18M5.23B
Pre-Tax Income % of Revenue i-36.5%
Income Tax iN/A725.80M
Income Tax % of Revenue i-5.1%
Net Income (Profit) i-12.18M4.50B
Profit Margin i-31.4%

Balance Sheet & Liquidity Metrics

MetricCWBR (2022)REGN (2025)
Cash & Equivalents i5.93M3.12B
Total Current Assets i16.22M18.02B
Total Current Assets % of Revenue i-125.7%
Total Current Liabilities i1.03M4.37B
Total Current Liabilities % of Revenue i-30.5%
Long-Term Debt iN/A2.71B
Long-Term Debt % of Revenue i-18.9%
Total Shareholders Equity i15.33M31.26B
Retained Earnings i-96.91M35.80B
Retained Earnings % of Revenue i-249.6%
Property, Plant & Equipment i412,7411.54B

Cash Flow Statement Comparison

MetricCWBR (2022)REGN (2025)
Operating Cash Flow i-10.42M6.30B
Operating Cash Flow % of Revenue i-43.9%
Capital Expenditures i103,5310
Free Cash Flow i-10.45M3.77B
FCF Margin i-26.3%
Debt Repayment i-375,000N/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricCWBRREGN
Shares Short iN/A2.55M
Short Ratio iN/A4.46
Short % of Float iN/A2.55%
Shares Outstanding i2.91M105.72M
Float Shares i2.48M98.55M
% Held by Insiders i15.09%1.98%
% Held by Institutions i6.24%91.08%
% Held by Public i78.67%6.94%

Dividend Analysis & Yield Comparison: Cohbar Inc vs Regeneron Pharmaceuticals, Inc.

MetricCWBRREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026